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Objective:
 
 To estimate the incidence and associated cost
of hospitalizations for toxicities associated with 5-fluo-
rouracil (5-FU) among patients with metastatic colorec-
tal cancer.
 
Methods:
 
 Using the 1994 Medicare 5% sample, we
identified all patients with metastatic colorectal cancer
who had undergone colorectal surgery. We then strati-
fied them into those who received 5-FU therapy within
90 days of their surgery (5-FU group) and those who
 
did not receive chemotherapy (no-chemotherapy group);
patients who received chemotherapeutic agents other
than 5-FU were excluded from the sample. Using tech-
niques of survival analysis, we then compared the inci-
dence and associated cost of all hospital admissions
 
with listed International Classification of Disease, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnostic
codes (primary or secondary) for conditions possibly re-
lated to 5-FU toxicity (e.g., volume depletion, stomati-
tis, nausea, and vomiting).
 
Results:
 
 A total of 441 patients met all study entry cri-
teria, including 192 who received 5-FU and 249 who
did not receive chemotherapy following surgery. Pa-
tients in the 5-FU group were younger than those in the
 
no-chemotherapy group (
 
p
 
 
 

 
 .001). Mean (
 

 
 SD) fol-
 
low-up time was slightly longer in the 5-FU group (137 
 

 
96 days vs. 117 
 

 
 88 days for no chemotherapy). The
incidence of toxicity-related hospitalizations at 10.5
months (principally volume depletion, agranulocytosis,
gastroenteritis, and nausea and vomiting) was 31%
among patients who received 5-FU and 8% among
those who did not receive chemotherapy. The cost of
inpatient care at 10.5 months was $2716 higher among
5-FU patients.
 
Conclusions:
 
 Hospitalization for toxicity of Medicare
 
patients with metastatic colorectal cancer receiving 5-FU
is frequent and costly.
 
Keywords:
 
 5-fluorouracil, colorectal-cancer, cost-analy-
sis, costs, toxicity.
 
Introduction
 
Among neoplastic diseases, colorectal cancer ranks
second only to lung cancer as a cause of death in
the United States [1]. Approximately 150,000 cases
of colorectal cancer are newly diagnosed each year,
and approximately 20% of these cases present with
metastases [2]. Most patients with newly diagnosed
metastatic colorectal cancer undergo surgery, after
which approximately one-half receive chemother-
apy, typically with 5-fluorouracil (5-FU) combined
with leucovorin [3].
Treatment with 5-FU has been shown to pro-
long survival in patients with metastatic colorectal
cancer [4–7]. It can also cause significant toxicity,
however, including stomatitis, nausea and vomit-
ing, diarrhea, leukopenia, thrombocytopenia, and
dermatitis [8–30]. The incidence of 5-FU toxicity
varies widely with the method of administration
(bolus vs. continuous infusion) and dosage, as well
as with the patient’s age, sex, nutritional status,
and concomitant diseases [9,30]. In randomized
controlled trials of 5-FU therapy for metastatic
colorectal cancer, the incidence of severe side ef-
fects has been reported to range from 0% to 28%
for stomatitis, 5% to 8% for nausea and vomit-
ing, 13% to 32% for diarrhea, and 3% to 29%
for leukopenia.
Frequently, 5-FU toxicity results in dose modi-
fication and/or therapy discontinuation. It can also
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result in hospitalization, thereby increasing costs
of care. The rate of hospitalization for severe side
effects among patients receiving 5-FU plus leuco-
vorin for treatment of metastatic colorectal cancer
has been reported in two clinical trials to date
[4,29]. The difference in the rate reported in these
studies was more than six-fold (5% vs. 31% at
approximately 24 months), possibly reflecting dif-
ferences in dosing, frequency of administration,
and clinical management. The incidence and asso-
ciated cost of hospitalization for 5-FU toxicity in
typical clinical practice is unknown. We address
this issue in our study, using data from a nationally
representative sample of Medicare beneficiaries.
 
Methods
 
Overview
 
We undertook a retrospective examination of the in-
cidence and cost of hospitalization for 5-FU toxicity
among patients with metastatic colorectal cancer,
using claims data from the 1994 Medicare 5% sam-
ple. Approximately two-thirds of patients with col-
orectal cancer are 65 years of age or older and there-
fore eligible for Medicare [31]. Medicare claims
data have been used in other studies of the incidence
and costs of colorectal and other cancers, and inci-
dence rates derived from these data have been shown
to be comparable to those reported by the Surveil-
lance, Epidemiology, and End Results (SEER) pro-
gram of the National Cancer Institute [32–37].
Since admission diagnoses potentially related to
5-FU toxicity (e.g., volume depletion) are not spe-
cific to 5-FU therapy, we compared the incidence
and cost of such admissions between patients with
metastatic colorectal cancer who received 5-FU
therapy and those who did not receive any chemo-
therapy. To ensure the comparability of the two
groups with respect to disease severity, we selected
patients who recently had undergone surgery for
colorectal cancer. Surgery was used as the marker
for disease severity for two principal reasons: first,
because most patients with newly diagnosed meta-
static colorectal cancer undergo surgery while most
with recurrent metastatic disease (for which prog-
nosis is generally believed to be worse) do not, pa-
tients undergoing surgery are much more likely to
have incident disease than recurrent disease [2];
and second, the fact that a physician has chosen
surgical treatment for a patient with metastatic
colorectal cancer suggests that the patient has a
relatively favorable prognosis and appears healthy
enough to survive the stress associated with sur-
gery.
 
Data Source
 
Data for this study were obtained from the 1994
Medicare 5% sample, which contains a complete
record of all bills submitted to Medicare for ser-
vices provided in calendar year 1994 for a 5%
random sample of Medicare beneficiaries, includ-
ing all institutional (hospital inpatient, nursing home,
and hospice), provider (physician services and phy-
sician-ordered supplies and services), and hospital
outpatient claims. All claims include beneficiary
identifiers, which may be used to link claims for
individual patients to construct a longitudinal his-
tory of all health-care services that were billed to
Medicare.
Institutional claims include one to nine Interna-
tional Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnostic codes,
up to five ICD-9-CM procedural codes, the quar-
ter during which the service was rendered, the
dates of any procedures, and patients’ discharge
disposition (e.g., discharged home, discharged to
nursing home, discharged dead). Provider claims
include up to nine ICD-9-CM diagnostic codes, up
to 56 Health Care Financing Administration Com-
mon Procedure Coding System (HCPCS) or Physi-
cian’s Current Procedural Terminology, 4th Edi-
tion (CPT-4) codes, the dates on which all services
were rendered, and the setting in which these ser-
vices were rendered (i.e., inpatient or outpatient).
Outpatient claims include up to nine ICD-9-CM
diagnostic codes, up to 56 procedural codes in
HCPCS or CPT-4 format, and the quarter during
which the services were rendered. All claims in-
clude billed charges, payments, and the date of re-
ceipt of the claim by Medicare.
 
Sample Selection
 
We selected all persons with one or more inpatient
claims with a diagnosis of malignant neoplasia of
the colon (ICD-9-CM 153.X) or rectum (154.0,
154.1), a diagnosis of secondary malignant neopla-
sia of the respiratory and digestive systems (197.X),
other specified sites (198.X), or distant lymph
nodes (196.0, 196.1, 196.2 [rectum only], 196.3,
196.5, 196.6 [colon only], 196.8, and 196.9), and
a procedure code for colon resection (ICD-9-CM
45.7X), total colectomy (45.8), colostomy (46.1X),
ileostomy (46.2X), or rectal resection (48.4X, 48.5,
48.6X). Coincident inpatient provider claims were
also scanned to identify those with CPT-4 codes
corresponding to these ICD-9-CM procedure codes
of interest. All patients who died during these hos-
pitalizations were excluded from the sample, as were
 Incidence and Cost of 5-FU Toxicity
 
37
 
those who received any chemotherapy before ad-
mission, those younger than 65 or older than 84
years of age, persons enrolled in health mainte-
nance organizations, and those for whom Medi-
care was not the primary health insurer.
Subjects with a provider or outpatient claims
for administration of 5-FU (HCPCS J9190) within
90 days following the date of colorectal surgery
were assigned to the 5-FU group. A 90-day win-
dow was chosen based on a review of the distribu-
tion of time from surgery to receipt of 5-FU in our
sample and is consistent with inclusion criteria in
clinical trials of this therapy [9,21,26]. Those with
no provider or outpatient claims for chemother-
apy (HCPCS codes J9000–J9999, Q0083–Q0085,
or CPT-4 codes 96400–96549) between the date
of surgery and the end of calendar year 1994 were
assigned to the no-chemotherapy group. Because
5-FU toxicity may occur less frequently with con-
tinuous infusion than with bolus administration,
and because infusion is rarely employed in the
United States, we excluded all subjects in the 5-FU
group who had claims associated with use of am-
bulatory or parenteral infusion pumps (HCPCS
E0781 and E0791, respectively) or provider claims
for initiation of prolonged infusion (CPT-4 code
96414). Patients who received chemotherapeutic
agents other than 5-FU following surgery were with-
drawn from the sample.
To identify patients who received 5-FU within
90 days of the date of colorectal surgery, dates of
service were needed. These dates were available
for provider claims but not for outpatient claims
for 5-FU, for which only the annual quarter in which
the claim was made was available. We therefore
estimated the date of each service using either the
last day of the quarter in which the service was
provided or the date of receipt of the claim minus
27 days (the mean number of days between the
dates of inpatient procedures and the receipt of
corresponding hospital claims), whichever came
first.
An index date was assigned to each subject in
the 5-FU group based on the date of the first claim
for 5-FU therapy. The index date for patients in
the no-chemotherapy group was determined ac-
cording to the date of surgery plus the mean num-
ber of days between dates of surgery and first ad-
ministration of 5-FU for patients in the 5-FU
group (mean [ 
 

 
 SD]: 41 [ 
 

 
 16] days). Patients in
the no-chemotherapy group who died between the
date of surgery and their assigned index date were
excluded from the sample, as were those whose
assigned index date was after December 31, 1994.
 
Study Measures
 
Attention was focused on the incidence and ex-
pected cost of hospitalizations with diagnoses re-
lated to 5-FU toxicity between the index date and
December 31, 1994 (i.e., the end of follow-up).
Hospitalizations related to 5-FU toxicity were iden-
tified based on the following primary or secondary
diagnoses: volume depletion (ICD-9-CM 276.5);
agranulocytosis (288.0); toxic and other unspeci-
fied noninfectious gastroenteritis (558.2, 558.9);
stomatitis (528.0); secondary and unspecified throm-
bocytopenia (287.4, 287.5); nausea and vomiting
(787.0), and dermatitis due to substances taken in-
ternally (693.X).
To identify hospitalizations that occurred during
follow-up as well as all inpatient services provided
during hospitalization, it was necessary to match
provider claims to hospital claims. Matching pro-
vider claims were defined as those for which dates
of service were concurrent with hospital stays.
Since hospital claims did not include dates of ad-
mission and discharge, these were estimated using
the date of receipt of the hospital claim, the last
date of the quarter in which hospital services were
rendered, the date of service of the principal hospi-
tal procedure (where applicable), and the dates of
the first and last concurrent provider claims.
Medicare payments were used as a proxy for
costs. The cost of each hospitalization was calcu-
lated by adding all payments for hospital and pro-
vider inpatient services associated with the stay.
 
Statistical Analyses
 
Selected characteristics were compared between
the 5-FU group and the no-chemotherapy group,
including age, gender, and race, as well as the geo-
graphic location and teaching status of the hospi-
tal in which initial surgery was performed. Statisti-
cal comparisons were undertaken using two-sided
chi-square statistics and Student’s 
 
t
 
-tests.
To account for differential follow-up, risk of
hospitalization between the index date and the
end of follow-up was estimated for each group us-
ing techniques of survival analysis. Subjects were
considered as being censored as of December 31,
1994. Survival curves for time to hospitalization
were generated using the Kaplan-Meier method
[38]. Since toxicity to 5-FU has been reported to
vary with patient’s age [30], risk of hospitalization
also was examined within strata defined on the
basis of age (65–74 vs. 75–84 years). A two-sided
log-rank statistic was used to compare survival
curves for the two treatment groups on the basis
of time to hospitalization [39]. The hazard ratio
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for hospitalization (and corresponding 95% confi-
dence interval) was estimated using a Cox propor-
tional hazards model [40].
The expected cost of hospitalization was com-
pared between the two treatment groups using
techniques described by Lin and colleagues [41].
The follow-up period for each patient was parti-
tioned into 1-day intervals. Kaplan-Meier esti-
mates of the probability of survival to the begin-
ning of each interval were then calculated for each
group. The expected cost of hospitalization in each
group was then calculated as the sum of the Kaplan-
Meier estimates of the probability of survival at
the beginning of each interval multiplied by corre-
sponding estimates of the mean cost of hospitaliza-
tions during the interval conditional on survival to
the beginning of the interval. A 95% confidence
interval for the expected cost of hospitalization
was calculated using methods for variance estima-
tion described by Lin and colleagues [41].
Use of this method required estimation of the
time to death or end of follow-up for all study
subjects. Since the Medicare 5% sample does not
explicitly include information on vital status, we
assumed that patients had died if they had any in-
stitutional claim for which the discharge destin-
ation was noted as death, and date of death was
assumed to be the date of discharge. We also as-
sumed that patients who had more than a 90-day
lag between their last provider claim and the end
of follow-up had died as of the date of their last
claim. The 80th percentile of the distribution of study
subjects according to maximum time between
consecutive provider claims was 90 days. Because
estimates of expected costs are based on survival
probabilities, survival curves for both groups are re-
ported. These were compared using a two-sided
log-rank statistic. The hazard ratio for death (and
corresponding 95% confidence interval) was esti-
mated using a Cox proportional hazards model
with age as a covariate.
All analyses were performed with the Statistical
Analysis System (SAS) Version 6.12 [42] (1990,
Cary, North Carolina, USA).
 
Results
 
Patient Characteristics
 
We identified 2908 patients with one or more
listed diagnoses of metastatic colorectal cancer in
the 1994 Medicare 5% sample. Of these, 790 un-
derwent colorectal surgery for their disease during
this year and 739 of these were discharged alive. A
 
total of 441 patients met all other inclusion crite-
ria, including 192 who received 5-FU and 249
who did not receive chemotherapy following sur-
gery (Table 1). Patients who received 5-FU were
younger than those in the no-chemotherapy group
(
 
p
 
 
 

 
 .001). Gender and race were similar in the
two groups. Mean (
 

 
 SD) follow-up time was
slightly longer in the 5-FU group (137 
 

 
 96 vs.
117 
 

 
 88 days for no chemotherapy). Maximum
follow-up time was 342 and 321 days (11.2 and
10.5 months) in the 5-FU and no-chemotherapy
groups, respectively. Slightly more patients in the
no-chemotherapy group had an index date in the
fourth quarter of 1994, although this difference
was not significant.
 
Mortality
 
Twenty-five (13%) and 42 (17%) patients in the
5-FU and no-chemotherapy groups, respectively,
had institutional claims in which the discharge
disposition was noted as death. Another 3 (2%)
and 21 (8%) patients, respectively, had more than
a 90-day lag between their last claim and the end
of follow-up (and therefore were assumed to have
died as of the date of their last claim). Using Kaplan-
Meier methods to control for differential follow-
up, mortality at 10.5 months was estimated to be
24% in the 5-FU group and 33% in the no-che-
motherapy group (Fig. 1). This difference was sta-
tistically significant (two-sided log-rank statistic, 
 
p
 
 
 

 
.028). The estimated hazard ratio for death among
patients in the 5-FU group was 0.59 (95% CI
0.37–0.94).
 
Table 1
 
Characteristics of study subjects, by treatment 
group
 
Characteristic
%
5-FU
% No
Chemotherapy
 
P
 
-value
Age (%) in years .001
65–69 26.6 19.7
70–74 34.9 23.7
75–80 23.4 27.3
81–84 15.1 29.3
Gender (% female) 49.5 56.6 .136
Race (% white) 90.1 88.4 .512
Hospital region (%) .066
Northeast 21.4 20.6
Midwest 27.6 26.6
South 40.6 33.5
West 10.4 19.4
Index date (%) .786
January–March 15.1 12.1
April–June 26.6 26.9
July–September 26.0 25.7
October–December 32.3 35.3
Teaching hospital (%) 43.1 42.3 .872
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Incidence of Hospitalization
 
The numbers of toxicity-related hospitalizations
among 5-FU and no-chemotherapy patients were
53 and 20, respectively. Many hospitalizations in-
cluded two or more relevant diagnoses. The most
common diagnoses among patients receiving 5-FU
were volume depletion, agranulocytosis, and nau-
sea and vomiting (Table 2). Among patients who
did not receive chemotherapy, the most common
diagnoses were volume depletion, gastroenteritis,
thrombocytopenia, and nausea and vomiting. There
were no hospitalizations for dermatitis or stomati-
tis in either group.
The incidence of hospitalization with diagnoses
related to 5-FU toxicity at 10.5 months was 31%
among patients receiving 5-FU and 8% among
those who did not receive chemotherapy (Fig. 2).
Time to hospitalization was significantly shorter
among patients in the 5-FU group (two-sided log-
rank statistic, 
 
p
 
 
 

 
 .001). The incidence of hospi-
 
talization did not differ by age. The estimated haz-
ard ratio for hospitalization for patients in the 5-FU
group was 3.26 (95% CI 1.77–5.77).
 
Cost of Hospitalization
 
The expected cost of hospitalization with diag-
noses related to 5-FU toxicity at 10.5 months was
estimated to be $3674 per patient in the 5-FU
group (95% CI $2981–$4368) and $958 per patient
in the no-chemotherapy group (95% CI $821–
$1096) (Fig. 3).
 
Discussion
 
While treatment with 5-FU plus leucovorin has
been reported to prolong survival in patients with
metastatic colorectal cancer, it can also cause sig-
nificant toxicity, potentially resulting in hospital-
ization. In this study, we used data from the 1994
Medicare 5% sample to estimate the cumulative
incidence and cost of hospitalization for 5-FU tox-
icity among patients with metastatic colorectal
cancer who underwent colorectal surgery during
that year. Patients who were treated with 5-FU
within 90 days of surgery were compared with
those who did not receive chemotherapy. At 10.5
months, the incidence of hospitalizations with ad-
mitting diagnoses potentially related to drug tox-
icity was 31% among patients receiving 5-FU; the
rate among patients who did not receive chemo-
therapy was only 8%. The expected cost per pa-
tient of toxicity-related admissions was approxi-
mately $2700 higher among 5-FU patients.
Our estimate of the rate of hospitalization with
toxicity-related diagnoses among patients receiv-
ing 5-FU (31% at 10 months) is at the upper end
of the range of previously reported estimates (5–31%
Figure 1 Estimated survival among patients with metastatic
colorectal cancer.
 
Table 2
 
Number of hospitalizations for 5-FU toxicity, by diagnosis and treatment group
 
Treatment
Toxicity-related diagnoses (n,%)
5-FU
(N 
 

 
 192)
No Chemotherapy
(N 
 

 
 249)
Volume depletion 23 12.0 10 4.0
Agranulocytosis 8 4.2 0 0.0
Nausea and vomiting 4 2.1 2 0.8
Gastroenteritis 3 1.6 4 1.6
Thrombocytopenia 0 0.0 2 0.8
Volume depletion and agranulocytosis 5 2.6 0 0.0
Volume depletion and gastroenteritis 2 1.0 1 0.4
Volume depletion and nausea and vomiting 1 0.5 1 0.4
Agranulocytosis and gastroenteritis 1 0.5 0 0.0
Volume depletion, agranulocytosis, and nausea and vomiting 4 2.1 0 0.0
Volume depletion, gastroenteritis, and nausea and vomiting 1 0.5 0 0.0
Agranulocytosis, gastroenteritis, thromobocytopenia 1 0.5 0 0.0
Total 53 27.6 20 8.0
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at approximately 24 months) [4,29], as is our esti-
mate of the associated expected cost of hospital-
ization among these patients [29]. This may reflect
the fact that all of the patients in our study were
over the age of 65 years, while prior studies have
included younger patients as well. Risk of 5-FU
toxicity has been reported to increase with age.
For example, in a recent randomized controlled trial
comparing 5-FU to two combination regimens of
5-FU plus leucovorin in patients with metastatic
colorectal cancer, those aged 70 years or older
were reported to have a 2.4-fold greater risk of se-
vere leukopenia, a 3-fold greater risk of severe vom-
iting, and a 1.7-fold greater risk of severe diarrhea
compared with patients who were younger [30].
It is surprising that we did not identify any hospi-
talizations for stomatitis (ICD-9-CM 528.0) among
patients receiving 5-FU, as the reported incidence
of severe mucositis has been high in many clinical
trials [4,12,13,15,18,23–25,27,29]. Although we
do not know the precise reason, we suspect that
this finding may be an artifact of coding, as pa-
tients admitted for the treatment of stomatitis may
receive diagnoses of volume depletion or possibly
agranulocytosis. The entry for mucositis in the
ICD-9-CM alphabetic index provides a cross-ref-
erence to agranulocytosis 288.0 [43].
Our finding that only 43% of patients with sur-
gically resected metastatic colorectal cancer re-
ceived 5-FU also is surprising in light of its proven
benefits [9]. It is consistent, however, with data
from the National Cancer Database for 1992, which
reported that only one-half of all patients with in-
cident stage IV colon or rectal cancer who under-
went surgery also received chemotherapy [3]. Un-
dertreatment of patients with advanced colorectal
cancer may be a result of physician or patient be-
liefs that the negative effects of chemotherapy on
patients’ quality of life [44] outweigh its benefits.
We note some potential limitations of our study.
First, errors in ICD-9 coding may have biased our
results. For example, if the rate of miscoding for
metastatic disease was greater in the no-chemo-
therapy group than in the 5-FU group, the inci-
dence of the events of interest (which occur more
frequently in those with advanced disease, inde-
pendent of chemotherapy) could have been under-
estimated in the no-chemotherapy group and con-
sequently, overestimated the cost of 5-FU toxicity.
We feel that this is unlikely, however, because
cancer rates derived from Medicare claims data
have been reported to be quite similar to those
from the SEER program [36,45,46].
To the best of our knowledge, the ability of
Medicare claims data to accurately distinguish met-
astatic from nonmetastatic disease has not been in-
vestigated per se. In the Cooper study, the median
percentage of incident cases with codes for distant
metastases in the Medicare data set (23.4%) was
higher than the median percentage of incident co-
lon cancer cases with distant metastases reported
by SEER (17.3%). Much of the difference may be
explained by the fact that the Medicare data in-
cluded only hospitalized cases, while the SEER da-
tabase (as the authors point out) probably includes
very early cases that were treated in an outpatient
setting. This would explain both the higher inci-
dence rates and the lower proportion of cases with
metastatic disease reported by SEER. We therefore
believe that our requirement that study subjects
have codes for both a primary colorectal tumor
and metastatic disease was highly specific for ad-
vanced disease (i.e., codes for metastatic disease
Figure 2 Estimated incidence of hospitalization for 5-FU
toxicity, by treatment group and days from index date.
Figure 3 Expected cost of 5-FU toxicity, by treatment group
and days from index date.
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would not have been used for patients with early
cancer).
To make our 5-FU and no-chemotherapy groups
as similar as possible, we limited our attention to
patients who had recently undergone surgery for
metastatic colorectal cancer. Patients in the 5-FU
group nonetheless may have differed significantly
from those in the no-chemotherapy group, and the
possibility of selection bias therefore must be ac-
knowledged. Differences in the incidence and cost
of hospitalization thus may reflect underlying dif-
ferences in the clinical status (and hence in likeli-
hood of hospitalization) of patients who received
5-FU versus those who did not receive chemother-
apy, rather than the effects of treatment per se. We
suspect that any such phenomenon would lend a
conservative bias to our findings, because patients
who elect not to receive chemotherapy are likely to
have more advanced disease and/or be in poorer
health than those who choose such treatment.
Hence they would be more (rather than less) likely
to be hospitalized for conditions such as volume
depletion and gastroenteritis. Our focus on pa-
tients who underwent recent surgery for meta-
static colorectal cancer means, however, that our
findings may not be generalized to patients who
are treated with chemotherapy only, those with
stage III disease, nonsurgical patients with recur-
rent metastatic colorectal cancer, and those with
other neoplasms.
Our estimate of mortality at 10 months among
patients receiving 5-FU (24%) is lower than that
reported in randomized controlled trials (30–60%)
[4,8,11,12–16,22–29]. In part, this difference may
reflect the fact that all the patients in our study
had undergone colorectal surgery, whereas other
trials have included surgical as well as nonsurgical
patients. The former may have a better prognosis
than the latter. It also is possible, however, that
we failed to identify some patients who in fact
died, because the Medicare 5% sample does not
explicitly include information on vital status. We
therefore assumed that patients had died if they
had any institutional claim for which the dis-
charge destination was noted as death, or if they
had more than a 90-day lag between their last
provider claim and the end of follow-up. While we
believe that these assumptions are reasonable, we
caution against placing undue reliance on our
mortality estimates. It should be noted, however,
that the primary measure of interest in this study
was the expected cost of 5-FU toxicity and not
mortality. Indeed, mortality and survival were es-
timated solely for the purpose of calculating ex-
 
pected lifetime costs. The effects of using a “proxy”
measure of mortality on our estimates of expected
costs are unknown. However, because mortality is
factored into both the numerator and the denomi-
nator of the equation that is used to estimate costs,
we believe that any underestimation of mortality is
unlikely to have materially affected our findings.
Given the frequent lack of data on time of death in
administrative data sets, additional research is
warranted to understand the potential biases that
use of such proxy measures imparts to estimates
of costs.
Finally, to maximize sample size, we included
patients with index dates as late as December 31,
1994. It is therefore possible that we assigned
some patients to our no-chemotherapy group who
underwent surgery in 1994 but only received che-
motherapy in 1995. We believe that any bias re-
sulting from these methods is negligible, because
our results were similar when we excluded pa-
tients with index dates in the fourth quarter of
1994. Also, some patients in the no-chemotherapy
group could have received (potentially toxic) che-
motherapy that was not billed to Medicare (e.g.,
experimental drugs). Any bias resulting from their
inclusion would likely be conservative.
In summary, our findings indicate that hospital-
ization for toxicity occurs frequently among Medi-
care patients with metastatic colorectal cancer, and
that the associated costs are substantial.
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